What about sentinel lymph node biopsy for early breast cancer during pregnancy?
| Autor: | Myriam Mimouni, P.M. David, C. Nos, M Deloménie, A S Bats, Vincent Balaya, Fabrice Lecuru, Marie Gosset, H Bonsang-Kitzis, Charlotte Ngo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
medicine.medical_specialty Sentinel lymph node Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer Pregnancy Biopsy medicine Humans 030212 general & internal medicine Radionuclide Imaging Lymph node Pathological Early breast cancer Fetus medicine.diagnostic_test Sentinel Lymph Node Biopsy business.industry Obstetrics and Gynecology medicine.disease Technetium Compounds medicine.anatomical_structure Reproductive Medicine 030220 oncology & carcinogenesis Female Radiology Radiopharmaceuticals business Pregnancy Complications Neoplastic |
| Zdroj: | Journal of Gynecology Obstetrics and Human Reproduction. 47:205-207 |
| ISSN: | 2468-7847 |
| Popis: | Pregnancy-associated breast cancer is rare, but this clinical situation arises in 1/10,000-1/3000 pregnancies. In patients presenting an early-stage breast tumor devoid of clinically pathological lymph node, sentinel lymph node (SLN) biopsy has not yet been validated as a routine procedure for pregnant women due to the lack of data in the literature. The blue dye injection is not recommended because of 2% theoretical risk of anaphylactic shock. Several studies have shown that Tc99m injection at conventional dose between 12.1 and 18.5MBq exposed the fetus to an irradiation between 0.011 and 0.0245mSv much below the 50mSv recommended threshold. As evidenced by lymphoscintigraphy scans, the dose of injected Tc99m is localized at the injection site and in the SLN. According to the literature, the SLN technique does not seem to impact the fetal or obstetrical prognosis. Studies involving larger cohorts are required to confirm these data and to indicate this technique in pregnant women. Considering the benefit for the patient and the low risk incurred on both fetal and obstetrical levels, it appears reasonable to discuss the indication of SLN on a case-by-case basis in multidisciplinary oncologic meetings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect